AI is accelerating drug discovery and compressing the timeline for critical intellectual property decisions. This article explores how biotech and pharmaceutical companies can build stronger patent strategies, documentation practices, and decision frameworks to protect innovation and long-term enterprise value.

As innovation accelerates, life sciences companies must align patent strategy with long-term growth. This update explores how portfolio design, operational structure, and early IP decisions shape flexibility, commercialization, and long-term value.

Early-stage IP decisions in life sciences often occur under pressure but carry long-term implications for licensing, valuation, and portfolio flexibility. This article explores how early patent strategy shapes commercialization outcomes.

Once you understand patent terms and regulatory exclusivity, the next step is designing a protection timeline for your product. This article shows how to combine US and EU rules, the EU Pharma Package, and development choices into a practical exclusivity map for your asset.

AI can accelerate discovery, but it can’t be the inventor. This guide explains how inventorship works in AI-assisted drug discovery, what can go wrong in real workflows, and how in-house teams can document human decision-making to protect patent enforceability and deal readiness.

In life sciences and advanced materials sector, IP due diligence is more than a legal formality; it’s central to valuation, deal viability, and long-term competitiveness. This article outlines a practical roadmap for investors and growth-stage companies to assess IP assets, FTO, risk, and strategy with the rigor these transactions demand.